Gαq-protein carboxyl terminus imitation polypeptide GCIP-27 attenuates cardiac hypertrophy in vitro and in vivo

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 12, 2007, Pages 1276-1281

  Zhang, Hai Gang ^a   Li, Xiao Hui ^a   Zhou, Jian Zhi ^a   Liu, Ya ^a   Jia, Yi ^a   Yuan, Zhi Bing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Calcium ion; Cardiac hypertrophy; G protein; Polypeptide drug; Proto oncogene; Signal transduction

Indexed keywords

ANGIOTENSIN II; G PROTEIN CARBOXYL TERMINUS IMITATION POLYPEPTIDE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LEUCINE; MESSENGER RNA; NORADRENALIN; POLYPEPTIDE; PROTEIN C JUN; UNCLASSIFIED DRUG; CALCIUM; GUANINE NUCLEOTIDE BINDING PROTEIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; HEART INDEX; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; GENETICS; HEART MUSCLE; METABOLISM; MOUSE; ONCOGENE; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM; CARDIOMEGALY; CELLS, CULTURED; GENES, FOS; GENES, JUN; GTP-BINDING PROTEINS; LEUCINE; MALE; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; NOREPINEPHRINE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 35549008480     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04716.x     Document Type: Article

References (37)

1. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: A new therapeutic target? Circulation 2004 109 : 1580 9.
2. Hu CM, Chen YH, Chiang MT, Chau LY. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 2004 110 : 309 16.
3. Molkentin JD. A friend within the heart: Natriuretic peptide receptor signaling. J. Clin. Invest. 2003 111 : 1275 7.
4. Kang YJ. Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicol. Pathol. 2006 34 : 58 66.
5. Zou Y, Hiroi Y, Uozumi H et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 2001 104 : 97 101.
6. Niu P, Shindo T, Iwata H et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis and renal damage. Circulation 2004 109 : 1789 94.
7. Bregagnollo EA, Okoshi K, Bregagnollo IF, Padovani CR, Okoshi MP, Cicogna AC. Effects of the prolonged inhibition of the angiotensin-converting enzyme on the morphological and functional characteristics of left ventricular hypertrophy in rats with persistent pressure overload. Arq. Bras. Cardiol. 2005 84 : 225 32.
8. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J. Hypertens. 1995 13 : 1091 5.
9. Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: The two faces of Janus. Am. J. Physiol. Heart Circ. Physiol. 2003 284 : H1043 7.
10. Harada K, Komuro I, Shiojima I et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998 97 : 1952 9.
11. Xu FP, Chen MS, Wang YZ et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004 110 : 1269 75.
12. Sugden PH. Signaling in myocardial hypertrophy: Life after calcineurin? Circ. Res. 1999 84 : 633 46.
13. q PLC β I, and PKC. Cardiovasc. Res. 1999 44 : 5 9.
14. Zhou JZ, Li XH, Zhang HG, Tang Y, Wang XQ. Cloning and gene expression of G protein competivive polypeptide and its prophylactic effects on myocardial hypertrophy in vitro. Acta Pharmacol. Sin. 2003 24 : 1108 12.
15. Zhang HG, Li XH. Optimization of G protein inhibitory polypeptide and its activities on cardiac hypertrophy. Acta Pharmacol. Sin. 2006 27 (Suppl 182 (Abstract).
16. Simpson P, Savion S. Differentiation of rat myocytes in single cell culture with and without proliferating nonmyocardial cells. Circ. Res. 1982 50 : 101 16.
17. Qin TC, Chen L, Yu LX, Gu ZL. Inhibitory effect of quercetin on cultured neonatal rat cardiomyocytes hypertrophy induced by angiotensin. Acta Pharmacol. Sin. 2001 22 : 1103 6.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951 193 : 265 75.
19. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline induced hypertrophy of cultured neonatal rat cardiomyocytes. Br. J. Pharmacol. 2001 132 : 159 64.
20. Tsoporis JN, Marks A, Kahn HJ et al. Inhibition of norepinephrine-induced cardiac hypertrophy in s100β transgenic mice. J. Chin. Invest. 1998 102 : 1609 16.
21. Marino TA, Cassidy M, Marino DR, Carson NL, Houser S. Norepinephrine-induced cardiac hypertrophy of the cat heart. Anat. Rec. 1991 229 : 505 10.
22. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000 35 : 985 91.
23. Hu CT, Chang HR, Hsu YH, Liu CJ, Chen HI. Ventricular hypertrophy and arterial hemodynamics following deprivation of nitric oxide in rats. Life Sci. 2005 78 : 164 73.
24. 2 in quiescent isolated rat cardiomyocytes. Basic Res. Cardiol. 2001 96 : 623 9.
25. 2+ transport mechanisms during the elusive moulting stage of crustaceans. Flow cytometry and polyclonal antibodies. J. Exp. Biol. 2001 204 : 959 66.
26. Adams JW, Pagel AL, Means CK, Oksenberg D, Armstrong RC, Brown JH. Cardiomyocyte apoptosis induced by Gαq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ. Res. 2000 87 : 1180 7.
27. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ. Res. 2003 92 : 725 31.
28. Anderson LL, Marshall GR, Crocker E, Smith SO, Baranski TJ. Motion of carboxyl terminus of Gα is restricted upon G protein activation. A solution NMR study using semisynthetic Gα subunits. J. Biol. Chem. 2005 280 : 31 019 26.
29. 2. Cell 1995 83 : 1047 58.
30. Lambright DG, Sondek J, Bohm A, Skiba NP, Hamm HE, Sigler PB. The 2.0 Å crystal structure of a heterotrimeric G protein. Nature 1996 379 : 311 19.
31. Kostenis E, Martini L, Ellis J et al. A highly conserved glycine within linker I and the extreme C terminus of G protein α subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity. J. Pharmacol. Exp. Ther. 2005 313 : 78 87.
32. Kostenis E, Gomeza J, Lerche C, Wess J. Genetic analysis of receptor-Gαq coupling selectivity. J. Biol. Chem. 1997 272 : 23 675 81.
33. 2A adenosine receptor. Mol. Pharmacol. 2000 58 : 226 36.
34. 2A adenosine receptor. Eur. J. Med. Chem. 2003 38 : 13 18.
35. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998 280 : 574 7.
36. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H8 16.
37. Adessi C, Soto C. Converting a peptide into a drug. Strategies to improve stability and bioavailability. Curr. Med. Chem. 2002 9 : 963 78.